SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 10-QSB


|X|   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934

                                   For the quarterly period ended March 31, 2005

|_|   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934

For the transition period from _______________ to _________________


                        Commission file number: 000-32253

                               SECURED DATA, INC.
--------------------------------------------------------------------------------
                     (formerly known as Secured Data, Inc.)
           (Name of Small Business Issuer as specified in its Charter)

              Nevada                                    87-0650264
 ---------------------------------        ------------------------------------
   (State or Other Jurisdiction           (I.R.S. Employer Identification No.)
 of Incorporation or Organization)

                   16B/F Ruixin Road Bldg. No. 25 Gaoxin Road
                      Xi An 710075 Shaanxi Province, China
              -----------------------------------------------------
           (Address of Principal Executive Offices Including Zip Code)


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. |X| Yes |_| No

The number of shares outstanding of the registrant's common equity as of May 18,
2005, was 93,604,958 shares of common stock, par value $0.001.

Transitional Small Business Disclosure Format (Check one): |_| Yes |X| No


                                       1
<PAGE>

                               SECURED DATA, INC.
                            INDEX TO THE FORM 10-QSB
                    FOR THE THREE MONTHS ENDED MARCH 31, 2005


                                TABLE OF CONTENTS


PART I.  FINANCIAL INFORMATION

Item 1.  Financial Statements

         Balance Sheet as of March 31, 2005 (unaudited)

         Statements of Operations for the three-month period Ended
         March 31, 2005 (unaudited)

         Statements of Cash Flows for the three-months ended March 31, 2005
         (unaudited)

         Notes to the Financial Statements

Item 2.  Management's Discussion and Analysis or Plan of Operation

Item 3.  Controls and Procedures

PART II. OTHER INFORMATION

Item 1.  Legal Proceedings

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

Item 3.  Defaults Upon Series Securities

Item 4.  Submission of Matters to a Vote of Security Holders

Item 5.  Other Information

Item 6:  Exhibits and Reports on Form 8-K

SIGNATURES


                                       2
<PAGE>

PART I.  FINANCIAL INFORMATION
Item 1.  Financial Statements

                       SECURED DATA, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEET

<TABLE>
<CAPTION>
                                                         ASSETS           March 31, 2005     December 31,
                                                                            (Unaudited)          2004
                                                                          --------------    --------------
<S>                                                                       <C>               <C>
CURRENT ASSETS
    Cash and cash equivalents                                             $      219,303    $      167,511
    Accounts receivable, net of allowances                                       504,967           104,144
    Inventories, net                                                           1,325,367         1,302,025
    Tax receivable                                                                 3,407                --
    Due from stockholders                                                        272,324            62,493
    Due from an associate                                                      1,665,459                --
    Other receivables                                                            371,054           335,058
                                                                          --------------    --------------
        Total Current Assets                                                   4,361,881         1,971,231

PROPERTY AND EQUIPMENT, NET                                                      862,080           879,503

LAND USE RIGHTS, NET                                                             133,288           133,974

OTHER ASSETS
    Investment in affiliate                                                       31,078            31,190
                                                                          --------------    --------------
TOTAL ASSETS                                                              $    5,388,327    $    3,015,898
                                                                          --------------    --------------


                                   LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts payable                                                      $       77,562    $       56,454
    Other payables and accrued expenses                                          162,472           145,191
    Value added tax payables                                                          --            12,323
    Income tax and other tax payables                                              6,899             6,684
    Convertible note payable                                                   1,900,000         1,900,000
    Due to stockholders                                                           73,868           193,433
                                                                          --------------    --------------
        Total Current Liabilities                                              2,220,801         2,314,085
                                                                          --------------    --------------

COMMITMENTS AND CONTINGENCIES                                                         --                --

MINORITY INTEREST                                                                 56,832            58,915
                                                                          --------------    --------------

STOCKHOLDERS' EQUITY
    Preferred stock, $0.001 par value, 5,000,000 shares authorized,
        none issued and outstanding                                                   --                --
    Common stock, $0.001 par value, 100,000,000 shares authorized,
        93,604,958 shares issued and outstanding                                  93,605            93,605
    Additional paid-in capital                                                 5,497,563         3,082,105
    Retained earnings (deficit)
      Unappropriated                                                          (2,487,724)       (2,540,062)
      Appropriated                                                                 7,250             7,250
                                                                          --------------    --------------
        Total Stockholders' Equity                                             3,110,694           642,898
                                                                          --------------    --------------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                                $    5,388,327    $    3,015,898
                                                                          --------------    --------------
</TABLE>



    The accompanying notes are an integral part of these financial statements


                                       3
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
         CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                    For the Three     For the Three
                                                                    Months Ended      Months Ended
                                                                    March 31, 2005    March 31, 2004
                                                                    --------------    --------------
<S>                                                                 <C>               <C>
NET SALES                                                           $      926,538    $      533,619

COST OF SALES                                                             (816,815)         (462,086)
                                                                    --------------    --------------

GROSS PROFIT                                                               109,723            71,533
                                                                    --------------    --------------

OPERATING EXPENSES
    Selling expenses and distribution expenses                              16,394             7,522
    General and administrative expenses                                     42,076             8,800
    Depreciation and amortization                                           17,393            12,987
                                                                    --------------    --------------
           Total Operating Expenses                                         75,863            29,309
                                                                    --------------    --------------

INCOME FROM OPERATIONS                                                      33,860            42,224

OTHER INCOME (EXPENSE)
    Equity in loss of affiliate                                               (112)               --
    Interest income, net                                                        49               166
    Other income (expense), net                                             42,270            (1,107)
                                                                    --------------    --------------
           Total Other Income (expense)                                     42,207              (941)

                                                                    --------------    --------------
PROFIT FROM OPERATIONS BEFORE TAXES AND MINORITY INTEREST                   76,067            41,283

INCOME TAX EXPENSE                                                         (25,812)          (14,049)

MINORITY INTEREST                                                            2,083             2,110
                                                                    --------------    --------------

NET INCOME                                                                  52,338            29,344

OTHER COMPREHENSIVE  INCOME
    Foreign currency translation loss                                           --                --
                                                                    --------------    --------------

COMPREHENSIVE INCOME                                                $       52,338    $       29,344
                                                                    --------------    --------------

Net income per share-basic and diluted                              $           --    $           --
                                                                    --------------    --------------

Weighted average number of shares outstanding during the period -
    basic and diluted                                                   93,604,958        80,235,590
                                                                    --------------    --------------
</TABLE>



    The accompanying notes are an integral part of these financial statements


                                       4
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

<TABLE>
<CAPTION>
                                                                          For the Three     For the Three
                                                                          Months Ended      Months Ended
                                                                          March 31, 2005    March 31, 2004
                                                                          --------------    --------------
<S>                                                                       <C>               <C>
CASH FLOWS FROM OPERATING ACTIVITIES
    Net income                                                            $       52,338    $       29,344
    Adjusted to reconcile net loss to cash provided
       by (used in) operating activities:
       Depreciation and amortization - cost of sales                              56,221            17,167
       Depreciation and amortization                                              17,393            12,987
       Equity in loss of affiliate                                                   112                --
       Minority interest                                                          (2,083)           (2,110)
    Changes in operating assets and liabilities (Increase) decrease in:
       Accounts receivable                                                      (400,823)           87,860
       Inventories                                                               (23,342)          110,539
       Tax receivable                                                             (3,407)               --
       Other receivables                                                         (35,996)         (611,552)
       Increase (decrease) in:
       Accounts payable                                                           21,108              (837)
       Other payables and accrued expenses                                        17,281            13,784
       Value added tax payables                                                  (12,323)           40,085
       Income tax and other taxes payable                                            215             8,337
                                                                          --------------    --------------
       Net cash used in operating activities                                    (313,306)         (294,396)
                                                                          --------------    --------------

CASH FLOWS FROM INVESTING ACTIVITIES
    Decrease in notes receivable                                                      --           506,774
    Purchase of property and equipment                                           (55,505)           (1,779)
                                                                          --------------    --------------
       Net cash (used in) provided by investing activities                       (55,505)          504,995
                                                                          --------------    --------------

CASH FLOWS FROM FINANCING ACTIVITIES
    (Increase) decrease in due from stockholders                                (209,831)              249
    Increase in due from an associate                                         (1,665,459)               --
    Registered capital appropriation                                           2,415,458                --
    Decrease in notes payable                                                         --          (241,642)
    Decrease in due to stockholders                                             (119,565)               --
                                                                          --------------    --------------
       Net cash provided by (used in) financing activities                       420,603          (241,393)
                                                                          --------------    --------------

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                              51,792           (30,794)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                 167,511            95,803
                                                                          --------------    --------------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                                $      219,303    $       65,009
                                                                          --------------    --------------

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid during the period for:
    Income taxes                                                          $           --    $           --
                                                                          --------------    --------------

    Interest expenses                                                     $           --    $           --
                                                                          --------------    --------------

</TABLE>

    The accompanying notes are an integral part of these financial statements


                                       5
<PAGE>

                               SECURED DATA, INC.

              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
                                 March 31, 2005
   -------------------------------------------------------------------------


NOTE 1 - BASIS OF PRESENTATION

The unaudited condensed consolidated financial statements of Secured Data Inc.
and subsidiaries (the "Company") have been prepared in accordance with generally
accepted accounting principles for interim financial information and pursuant to
the requirements for reporting on Form 10-QSB and Item 310(b) of Regulation S-B.
Accordingly, they do not include all the information and footnotes required by
accounting principles generally accepted in the United States of America for
complete financial statements. However, such information reflects all
adjustments (consisting solely of normal recurring adjustments), which are, in
the opinion of management, necessary for the fair presentation of the
consolidated financial position and the consolidated results of operations.
Results shown for interim periods are not necessarily indicative of the results
to be obtained for a full year. The condensed consolidated balance sheet
information as of March 31, 2005 was derived from the audited consolidated
financial statements included in the Company's Annual Report Form 10-KSB. These
interim financial statements should be read in conjunction with that report.

Certain prior period amounts have been reclassified to conform to the current
period's presentation.

NOTE 2 - USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements, and
the reported amounts of revenue and expenses during the reporting period. Actual
results when ultimately realized could differ from those estimates.

NOTE 3 - NATURE OF COMPANY

On December 20, 2004, pursuant to an agreement between the Company and Art
Malone, Jr. (the "Malone Agreement"), Art Malone, Jr. (the "Selling
Shareholder") sold 7,229,601 shares of the common stock of the Company for
$300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals on the closing
date of December 20, 2004. As a result, the 7,229,601 shares of the Company's
common stock sold represented approximately 56.18% of the total outstanding
shares of common stock of the Company. Immediately thereafter, on December 20,
2004 SCRE completed a Northwest Agreement, of which the Company initially
purchased 30% of the common shares of NBTI in exchange for 80,735,590 shares of
the Company's common stock ("Acquisition"). The purchase price for the remaining
70% of NBTI's common shares was $1,900,000 payable by the Company's issuance of
a promissory note ("Promissory Note") on December 20, 2004. The Promissory Note


                                       6
<PAGE>

may be convertible into 10,465,725 (post a one for eighteen reverse split)
shares of the Company's common stock. As a result, the 80,735,590 shares of the
Company's common stock sold represented approximately 86.3% of the total
outstanding stock of the Company. The Exchange resulted in a change of voting
control of the Company.

NBTI was incorporated in the British Virgin Islands on June 25, 2004. NBTI
operates through its wholly owned subsidiary, Huifeng Biochemistry Joint Stock
Company ("Huifeng"), which is a joint venture company established under the laws
of China and is engaged in the production and sales of plant extracts,
biochemical products and pharmaceutical raw products in the PRC.

The exchange was treated as a reverse acquisition for accounting purposes. As
such, the financial information reflected activity subsequent to the acquisition
for SCRE and its subsidiaries and financial activity of NBTI prior to the
acquisition. We will continue the business operations conducted by NBTI. All of
the information contained in the discussion of the Company's operations in this
section takes into account the historical business of NBTI, not Secured Data.

NOTE 4 - EARNINGS PER SHARE

Basic earnings per share are computed by dividing income available to common
shareholders by the weighted-average number of common shares outstanding during
the period. Diluted earnings per share is computed similar to basic earnings per
share except that the denominator is increased to include the number of
additional common shares that would have been outstanding if the potential
common shares had been issued and if the additional common shares were dilutive.
There was no dilutive security or common stock equivalent outstanding as of
March 31, 2005.

NOTE 5 - FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying value of financial instruments including cash and cash equivalents,
accounts receivable, advances to suppliers, other receivables accounts payable,
short-term bank loans, customer deposits, taxes payable, other payables and
accrued expenses and debt, approximates their fair value at March 31, 2005 and
December 31, 2004 due to the relatively short-term nature of these instruments.

NOTE 6 - INVESTMENT IN AFFILIATE

On June 16, 2004, the Company's subsidiary Xian Huifeng Biochemistry Joint-Stock
Company Limited ("Huifeng Biochemistry") acquired an 86.7% interest in Baoji
Jinsen Pharmaceutical Company Limited, later renamed to Xian Huifeng
Pharmaceutical Company Limited ("Huifeng Pharmaceutical"), which owns licenses
to manufacture two pharmaceutical products in the PRC. The balance of 13.3% is
held by a stockholder of the Company. On November 10, 2004 Huifeng
Pharmaceutical increased its registered capital from $181,159 to $603,865. The
increased registered capital was fully subscribed by a stockholder of the
Company, diluting the Company's interest in Huifeng Pharmaceutical from 86.7% to
26%. See note 8.

A summary of the unaudited financial statements of the affiliate as of March 31,
2005 and December 31, 2004 is as follows:


                                       7
<PAGE>

<TABLE>
<CAPTION>
                                                           2005
                                                        (Unaudited)           2004
                                                       --------------    --------------
<S>                                                    <C>               <C>
Current assets                                         $      434,181    $      425,641
Non-current assets                                          1,652,740             1,085
                                                       --------------    --------------
Total assets                                                2,086,921           426,727
                                                       --------------    --------------
Current liabilities                                         1,665,459             4,831
Stockholders' equity                                          421,462           421,896
                                                       --------------    --------------
Total liabilities and stockholders' equity             $    2,086,921    $      426,727
                                                       --------------    --------------
Revenue                                                $           --    $           --
                                                       --------------    --------------
Net loss from November 11, 2004 to December 31, 2004               --              (810)
                                                       --------------    --------------
Net loss from January 1, 2005 to March 31, 2005                  (433)               --
                                                       --------------    --------------

The Company's share of the loss for the period :
Company share at 26% and equity in loss of affiliate   $         (112)   $         (211)
                                                       --------------    --------------
</TABLE>

NOTE 7 - CAPITAL CONTRIBUTION

During the three months ended March 31, 2005, the Company's subsidiary Xian
Huifeng Biochemistry Joint-Stock Company Limited ("Huifeng Biochemistry")
contributed $2,415,459 to its registered capital.

NOTE 8 - RELATED PARTY TRANSACTIONS

The Company had advanced funds totaling $272,324 and $62,493 to stockholders as
of March 31, 2005 and December 31, 2004 respectively as short-term, unsecured
loans free of interest payment.

Stockholders had also advanced funds totaling $73,868 and $193,433 to the
Company as of March 31, 2005 and December 31, 2004 respectively as short-term,
unsecured loans free of interest payment.

During the quarter the Company advanced funds totaling $1,665,459 to its 26%
associate, Xian Huifeng Pharmaceutical Co. Ltd, of which $1,654,589 was advanced
for the purpose of increasing, subject to the PRC Government approval, the
Company's investment in the affiliate. When approved, the Company will increase
its interest in the affiliate from 26% to 80.2%.


NOTE 9 - FOREIGN CURRENCY CONVERSION

The Company's financial information is presented in US dollars. People's
Republic of China currency (Renminbi), the functional currency of the Company,
has been converted into US dollars at the exchange rate of 8.28 to 1.


Item 2.  Management's Discussion and Analysis or Plan of Operation.


                                       8
<PAGE>

This report contains forward-looking statements within the meaning of the
federal securities laws. These include statements about our expectations,
beliefs, intentions or strategies for the future, which we indicate by words or
phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe,"
"SCRE believes," "management believes" and similar language. The forward-looking
statements are based on the current expectations of SCRE and are subject to
certain risks, uncertainties and assumptions, including those set forth in the
discussion under "Management's Discussion and Analysis or Plan of Operation".
The actual results may differ materially from results anticipated in these
forward-looking statements. We base the forward-looking statements on
information currently available to us, and we assume no obligation to update
them.

On December 20, 2004, pursuant to an agreement between the Company and Art
Malone, Jr. (the "Malone Agreement"), Art Malone, Jr. (the "Selling
Shareholder") sold 7,229,601 shares of the common stock of the Company for
$300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals on the closing
date of December 20, 2004. As a result, the 7,229,601 shares of the Company's
common stock sold represented approximately 56.18% of the total outstanding
shares of common stock of the Company. Immediately thereafter, on December 20,
2004 SCRE completed a Northwest Agreement, of which the Company initially
purchased 30% of the common shares of NBTI in exchange for 80,735,590 shares of
the Company's common stock ("Acquisition"). The purchase price for the remaining
70% of NBTI's common shares was $1,900,000 payable by the Company's issuance of
a promissory note ("Promissory Note") on December 20, 2004. The Promissory Note
may be convertible into 10,465,725 (post a one for eighteen reverse split)
shares of the Company's common stock. As a result, the 80,735,590 shares of the
Company's common stock sold represented approximately 86.3% of the total
outstanding stock of the Company. The Exchange resulted in a change of voting
control of the Company.

NBTI was incorporated in the British Virgin Islands on June 25, 2004. NBTI
operates through its wholly owned subsidiary, Huifeng Biochemistry Joint Stock
Company ("Huifeng"), which is a joint venture company established under the laws
of China and is engaged in the production and sales of plant extracts,
biochemical products and pharmaceutical raw products in the PRC.

The exchange was treated as a reverse acquisition for accounting purposes. As
such, the financial information reflected activity subsequent to the acquisition
for SCRE and its subsidiaries and financial activity of NBTI prior to the
acquisition. We will continue the business operations conducted by NBTI. All of
the information contained in the discussion of the Company's operations in this
section takes into account the historical business of NBTI, not Secured Data.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

We have identified one policy area as critical to the understanding of our
consolidated financial statements. The preparation of our consolidated financial
statements requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the consolidated financial statements and the
reported amounts of sales and expenses during the reporting periods. With
respect to net realizable value of the Company's accounts receivable and


                                       9
<PAGE>

inventories, significant estimation judgments are made and actual results could
differ materially from these estimates.

The Company does not have any reserves against its accounts receivable or
inventories at March 31, 2005 and 2004. Management's estimation that there are
no reserves is based on the current facts that there are no significant aged
accounts receivable and the current inventory turnover is sufficient to realize
the current carrying value of the inventories. In making their judgment,
management has assumed that there will be continued demand for their products in
the future, thereby maintaining adequate turnover of the inventories.
Additionally, management has assumed that customers will continue to pay their
outstanding invoices timely, and that their customers' financial positions will
not deteriorate significantly in the future, which would result in their
inability to pay their debts to the Company. While the Company's management
currently believes that there is little likelihood that the actual results of
their current estimates will differ materially from its current estimates, if
customer demand for its products decreases significantly in the near future, or
if the financial position of its customers deteriorates in the near future, the
Company could realize significant write downs for slow moving inventories or
uncollectible accounts receivable.

We believe the following is among the most critical accounting policies that
impact our consolidated financial statements. We suggest that our significant
accounting policies, as described in our consolidated financial statements in
the Summary of Significant Accounting Policies, be read in conjunction with this
Management's Discussion and Analysis of Financial Condition and Results of
Operations.

We recognize revenue in accordance with Staff Accounting Bulletin ("SAB") No.
104. All of the following criteria must exist in order for us to recognize
revenue:

      1.    Persuasive evidence of an arrangement exists;

      2.    Delivery has occurred or services have been rendered;

      3.    The seller's price to the buyer is fixed or determinable; and

      4.    Collectibility is reasonably assured.

The majority of the Company's revenue results from sales contracts with
distributors and revenue is generated upon the shipment of goods. The Company's
pricing structure is fixed and there are no rebate or discount programs.
Management conducts credit background checks for new customers as a means to
reduce the subjectivity of assuring collectibility. Based on these factors, the
Company believes that it can apply the provisions of SAB 104 with minimal
subjectivity.


                                       10
<PAGE>

RESULTS OF OPERATIONS

The following table sets forth selected statement of operations data as a
percentage of revenues for the periods indicated.

                                               Three Months Ended
                                       March 31, 2005     March 31, 2004
                                       --------------     -------------

Revenues                                      100.00%               100%
Cost of Revenues                              (88.16%)           (86.59%)
Gross Margin                                   11.84%             13.41%
General and administrative expenses            (4.54%)            (1.65%)
Selling and distribution expenses              (1.77%)            (1.41%)
Depreciation and amortization                  (1.88%)            (2.43%)
Equity in loss of affiliate                    (0.01%)             0.00%
Interest income, net                            0.00%              0.03%
Other income (expense), net                     4.56%             (0.21%)
Income tax expenses                            (2.79%)            (2.63%)
Minority interest                               0.22%              0.40%
Net income                                      5.65%              5.50%


THREE MONTHS ENDED MARCH 31, 2005 COMPARED TO THREE MONTHS ENDED MARCH 31, 2004

Revenues, Cost of Revenues and Gross Margin

Revenues for the three months ended March 31, 2005 were $926,538, an increase of
$392,919 from $533,619 for the three months ended March 31, 2004. Our increases
in sales revenues in the first quarter of 2005 over the first quarter of 2004
were mainly attributable to the increase in our sales of Rutin related products.
The increase in demand for Rutin related products in China created a substantial
market for Rutin and resulted in increased sales of our Rutin products in the
first quarter of 2005 as compared to the first quarter of 2004.

Cost of revenues for the three months ended March 31, 2005 were $816,815, an
increase of $354,729 from $462,086 for the three months ended March 31, 2004.
Compared to the first quarter of 2005, the increase in cost of sales of our
products was because of our increase in sales revenue in the first quarter of
2005 as compared to the first quarter of 2004. However, the increase in cost of
sales of our products was not in the same proportion as our increase in sales
revenue because our profit margin decreased in the first quarter of 2005 as
compared to the first quarter of 2004.

Our gross profit margin for the three months ended March 31, 2005 deteriorated
from 13.4% for the first three months of 2004 to 11.8% for the first three
months of 2005. This slight decrease was a result of slight operational
inefficiencies which varied from quarter to quarter during the normal course of
production.

Gross margin for the three months ended March 31, 2005 was $109,723, an increase
of $38,190 from $71,533 for the three months ended March 31, 2004.

General and Administrative Expenses

General and Administrative expenses totaled $42,076 for the three months ended
March 31, 2005, an increase of $33,276 from $8,800 for the three months ended
March 31, 2004. The increase in general and administrative expenses was mainly
due to an increase in general and administrative expenses in Huifeng and SCRE as
a result of an increase in business activities.


                                       11
<PAGE>

Selling and Distribution Expenses

Selling and distribution expenses totaled $16,394 for the three months ended
March 31, 2005, an increase of $8,872 from $7,522 for the three months ended
March 31, 2004. The Company had increased its expenses in sales and distribution
with sales revenue increased in order to support the direct selling activities
to industrial customers.

Liquidity and Capital Resources

Cash

Our cash balance amounted to $219,303 at March 31, 2005.

In the three months ended March 31, 2005, our cash used in operating activities
totaled $313,306, mainly due to an increase in accounts receivable in the
three-month period, which totaled $400,823 and offset the net profit of $52,338.
In the three months ended March 31, 2005, cash flow used in investing activities
totaled $55,505. Cash flow from financing activities totaled $420,603.

The Company is currently funding its operations from, in addition to sales
revenues, loans from shareholders.

Working Capital

Our working capital amounted to $2,141,080 at March 31, 2005.

NEW ACCOUNTING PRONOUNCEMENTS

In January 2003, (as revised in December 2003) The Financial Accounting
Standards Board ("FASB") issued Interpretation No. 46(R), "Consolidation of
Variable Interest Entities", an interpretation of Accounting Research Bulletin
("ARB") No. 51, "Consolidated Financial Statements". Interpretation No. 46(R)
addresses consolidation by business enterprises of variable interest entities,
which have one or both of the following characteristics: (i) the equity
investment at risk is not sufficient to permit the entity to finance its
activities without additional subordinated support from other parties, which is
provided through other interest that will absorb some or all of the expected
losses of the entity; (ii) the equity investors lack one or more of the
following essential characteristics of a controlling financial interest: the
direct or indirect ability to make decisions about the entities activities
through voting rights or similar rights; or the obligation to absorb the
expected losses of the entity if they occur, which makes it possible for the
entity to finance its activities; the right to receive the expected residual
returns of the entity if they occur, which is the compensation for the risk of
absorbing the expected losses.

Interpretation No. 46(R), as revised, also requires expanded disclosures by the
primary beneficiary (as defined) of a variable interest entity and by an
enterprise that holds a significant variable interest in a variable interest
entity but is not the primary beneficiary. Interpretation No. 46(R), as revised,
applies to small business issuers no later than the end of the first reporting
period that ends after December 15, 2004.


                                       12
<PAGE>

This effective date includes those entities to which Interpretation 46 had
previously been applied. However, prior to the required application of
Interpretation No. 46(R), a public entity that is a small business issuer shall
apply Interpretation 46 or this Interpretation to those entities that are
considered to be special-purpose entities no later than as of the end of the
first reporting period that ends after December 15, 2003.

Interpretation No. 46(R) may be applied prospectively with a cumulative-effect
adjustment as of the date on which it is first applied or by restating
previously issued financial statements for one or more years with a
cumulative-effect adjustment as of the beginning of the first year restated.

In May 2003, the FASB issued SFAS No. 150, "Accounting For Certain Financial
Instruments with Characteristics of both Liabilities and Equity". SFAS No. 150
changes the accounting for certain financial instruments with characteristics of
both liabilities and equity that, under previous pronouncements, issuers could
account for as equity. The new accounting guidance contained in SFAS No. 150
requires that those instruments be classified as liabilities in the balance
sheet.

SFAS No. 150 affects the issuer's accounting for three types of freestanding
financial instruments. One type is mandatorily redeemable shares, which the
issuing company is obligated to buy back in exchange for cash or other assets. A
second type includes put options and forward purchase contracts which involve
instruments that do or may require the issuer to buy back some of its shares in
exchange for cash or other assets. The third type of instruments that are
liabilities under this Statement is obligations that can be settled with shares,
the monetary value of which is fixed, tied solely or predominantly to a variable
such as a market index, or varies inversely with the value of the issuers'
shares. SFAS No. 150 does not apply to features embedded in a financial
instrument that is not a derivative in its entirety.

Most of the provisions of SFAS 150 are consistent with the existing definition
of liabilities in FASB Concepts Statement No. 6, "Elements of Financial
Statements". The remaining provisions of this Statement are consistent with the
FASB's proposal to revise that definition to encompass certain obligations that
a reporting entity can or must settle by issuing its own shares. This Statement
shall be effective for financial instruments entered into or modified after May
31, 2003 and otherwise shall be effective at the beginning of the first interim
period beginning after June 15, 2003, except for mandatorily redeemable
financial instruments of a non-public entity, as to which the effective date is
for fiscal periods beginning after December 15, 2004.

In November 2004, the FASB issued SFAS No. 151 "Inventory Costs". This statement
amends the guidance in ARB No. 43, Chapter 4, "Inventory Pricing," to clarify
the accounting for abnormal amounts of idle facility expense, freight, handling
costs, and wasted material (spoilage). In addition, this Statement requires that
allocation of fixed production overhead to the costs of conversion be based on
the normal capacity of the production facilities. The provisions of this
Statement will be effective for the Company beginning in 2005.

In December 2004, the FASB issued SFAS No. 153, "Exchanges of Non-Monetary
Assets, an Amendment of Accounting Principles Board ("APB") No. 29". This
statement amends APB Opinion No. 29, "Accounting for Nonmonetary Transactions".
Earlier guidance had been based on the principle that exchanges of nonmonetary
assets should be based on the fair value of the assets exchanged and APB No. 29
included certain exceptions to this principle. However, FASB 153 eliminated the


                                       13
<PAGE>

specific exceptions for nonmonetary exchanges with a general exception rule for
all exchanges of nonmonetary assets that do not have commercial and economic
substance. A nonmonetary exchange has commercial substance only if the future
cash flows of the entity are expected to change significantly as a result of the
exchange. This statement is effective for nonmonetary exchanges occurring in
fiscal periods beginning after June 15, 2005.

In December 2004, the FASB issued a revised SFAS No. 123, Accounting for
Stock-Based Compensation, which supersedes APB opinion No. 25, Accounting for
Stock Issued to Employees, and its related implementation guidance. This
statement requires a public entity to recognize and measure the cost of employee
services it receives in exchange for an award of equity instruments based on the
grant-date fair value of the award (with limited exceptions). These costs will
be recognized over the period during which an employee is required to provide
service in exchange for the award - the requisite service period (usually the
vesting period). This statement also establishes the standards for the
accounting treatment of these share-based payment transactions in which an
entity exchanges its equity instruments for goods or services. It addresses
transactions in which an entity incurs liabilities in exchange for goods or
services that are based on the fair value of the entity's equity instruments or
that may be settled by the issuance of those equity instruments. This statement
shall be effective the first interim or annual reporting period that begins
after December 15, 2005 for small business public entities and nonpublic
companies.

The implementations of the above pronouncements are not expected to have a
significant effect on the Company's consolidated financial statement
presentation or disclosure.

INFLATION

Inflation has not had a material impact on our business.

CURRENCY EXCHANGE FLUCTUATIONS

All of the Company's revenues and a majority of the expenses in the first three
months of 2005 were denominated primarily in Renminbi ("RMB"), the currency of
The People's Republic of China. There can be no assurance that RMB-to-U.S.
dollar exchange rates will remain stable. A devaluation of the RMB relative to
the U.S. dollar would adversely affect our business, financial condition and
results of operations. We do not engage in currency hedging.

Item 3.  Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to
ensure that information required to be disclosed in the Company's Exchange Act
reports is recorded, processed, summarized and reported within the time periods
specified in the SEC's rules and forms, and that such information is accumulated
and communicated to the Company's management, including its Chief Executive
Officer and Chief Financial Officer, as appropriate, to allow timely decisions
regarding required disclosure based closely on the definition of "disclosure
controls and procedures" in Rule 13a-14(c). The Company's disclosure controls
and procedures are designed to provide a reasonable level of assurance of


                                       14
<PAGE>

reaching the Company's desired disclosure control objectives. In designing and
evaluating the disclosure controls and procedures, management recognized that
any controls and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired control objectives,
and management necessarily was required to apply its judgment in evaluating the
cost-benefit relationship of possible controls and procedures. The Company's
certifying officer has concluded that the Company's disclosure controls and
procedures are effective in reaching that level of assurance.

As of the end of the period of this report, the Company carried out an
evaluation, under the supervision and with the participation of the Company's
management, including the Company's Chief Executive Officer and the Company's
Chief Financial Officer, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures. Based on the foregoing, the
Company's Chief Executive Officer and Chief Financial Officer concluded that the
Company's disclosure controls and procedures were effective.

There have been no significant changes in the Company's internal controls or in
other factors that could significantly affect the internal controls subsequent
to the date the Company completed its evaluation.



PART II.  OTHER INFORMATION


Item 1.  Legal Proceedings:

We are currently not involved in any litigation that we believe could have a
material adverse effect on our financial condition or results of operations.
There is no action, suit, proceeding, inquiry or investigation before or by any
court, public board, government agency, self-regulatory organization or body
pending or, to the knowledge of the executive officers of our Company or any of
our subsidiaries, threatened against or affecting the Company, our common stock,
any of our subsidiaries or of our Company's or our Company's subsidiaries'
officers or directors in their capacities as such, in which an adverse decision
could have a material adverse effect.

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds:

None.

Item 3.  Defaults Upon Senior Securities:

None

Item 4. Submission of Matters to a Vote of Security Holders:

On March 23, 2005, the Board of Directors unanimously approved and ratified a
1:18 reverse split (the "Reverse Split") of the Company's issued and outstanding
common stock and an amendment (the "Amendment") to its Articles of Incorporation


                                       15
<PAGE>

changing the name of the Company to "Huifeng Bio-pharmaceutical Technology
Inc.", subject to the approval of the Company's stockholders. The record date
established by the Board for purposes of determining the number of outstanding
shares of voting stock entitled to vote on the Reverse Split and the Amendment
was March 23, 2005 (the "Record Date"). On the Record Date, stockholders owning
53,850,640 shares of Common Stock, or approximately 57.5% of the issued and
outstanding shares of Common Stock, approved the Reverse Split and the Amendment
by action taken without a meeting in accordance with Nevada law. No further vote
of our stockholders was required.

As a result, the Company filed a preliminary information statement pursuant to
Section 14(c) of the Securities Exchange Act of 1934 on March 23, 2005 in
connection with the approval by a majority of the stockholders of (i) an
amendment to its Articles of Incorporation effecting the Reverse Split and (ii)
the Amendment.

On the effective date of the Reverse Split the number of issued and outstanding
shares of common stock of the Company will be reduced from a total of 93,604,958
shares which were outstanding on the Record Date, to approximately 5,200,275
shares.

When filed with the Nevada Secretary of State, the Amendment will change the
name of the Company to "Huifeng Bio-pharmaceutical Technology Inc."

However, as of the date of this filing, this preliminary information statement
was still not approved by the Securities and Exchange Commission.

Item 5. Other Information:

None

Item 6.  Exhibits and Reports on Form 8-K

     (a) Exhibits

3.1.    Articles of Incorporation (1) 3.2 ByLaws (1)
3.3     Certificate of Amendment to Articles of Incorporation (2)
10.1    Amended Agreement and Plan of Reorganization dated July 13, 2004 (3)
31.1    Sarbanes Oxley Section 302 Certification
31.2    Sarbanes Oxley Section 302 Certification
32.1    Sarbanes Oxley Section 906 Certification
32.2    Sarbanes Oxley Section 906 Certification

(1)  Incorporated by Reference from the registration statement on form SB-2
     filed on or about July 28, 2000.

(2)  Incorporated by Reference from the registrant's quarterly report on Form
     10-qsb for the fiscal quarter ended March 31, 2004 filed on May 17, 2004.

(3)  Incorporated by Reference from registrant's current report on Form 8-k
     filed on August 11, 2004.

     (b) The following reports on Form 8-K were filed:


                                       16
<PAGE>

      o     February 4, 2005 to report the resignation of Art Malone as a
            director.
      o     March 11, 2005 to report the Transaction.
      o     March 18, 2005 to report the change in accountant.
      o     April 7, 2005 to report the change in accountant.
      o     April 22, 2005 to report the change in accountant.
      o     May 12, 2005 to report the Transaction.



                                   SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this Report to be signed
on its behalf by the undersigned, thereunto duly authorized this 20th day of May
2005.


                                                  SECURED DATA, INC.

                                            By:   /s/ JING AN WANG
                                                  -----------------------
                                                  Jing An Wang
                                                  Chief Executive Officer


                                       17